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Key Points:  
There is: 
 A significant difference between official rules and guidelines  and primary care physicians’ (PCP’s)  
attitudes to dementia management 
 A high variability of PCP’s attitudes towards dementia management and of rules regarding who has 
the right to start or continue dementia specific therapy across 25 European and Mediterranean  
countries 
 A consistent association between national rules and PCPs’ level of activity in dementia so that the 
more the GPs are allowed to do the more they engage in dementia workup and treatment 
 A dominant part of PCPs in the 25 countries claim that the Mini Mental State Examination is the 
most popular cognitive test. 
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Abstract 1 
Objective:  Strategies for the involvement of primary care in the management of patients with 2 
presumed or diagnosed dementia are heterogeneous across Europe and the Mediterranean area. We 3 
wanted to explore attitudes of primary care physicians (PCP) when managing dementia: i) the most 4 
popular cognitive tests ii) who had the right to initiate or continue cholinesterase inhibitor or 5 
memantine treatment and iii) the relationship between the permissiveness of these rules/guidelines 6 
and PCP’s approach in the dementia work-up. Design: Key informant Survey. Setting: Primary 7 
care practices across 25 European and Mediterranean countries. Subjects: Four hundred forty-five 8 
PCPs responded to a self-administered questionnaire. Main outcome measures: Two by two 9 
contingency tables with odds ratios and 95% confidence intervals were used to assess the 10 
association between categorical variables. A multinomial logistic regression model was used to 11 
assess the association of multiple variables (age class, gender and prescription rules) with the 12 
attitude to start dementia evaluation by PCPs. Results: Discrepancies between rules/guidelines and 13 
attitudes to dementia management was found in many countries. The Mini-Mental State 14 
Examination (MMSE) was by far the most popular cognitive test followed by the Clock Drawing 15 
Test (CDT). Lack of time was the major stated reason for not diagnosing dementia. There was 16 
a strong association between the authorization to prescribe dementia drugs and pursuing dementia 17 
diagnostic work-up (odds ratio, 3.45; 95% CI 2.28- 5.23).  Conclusions: Differing regulations 18 
about who does what in dementia management seems to affect PCP’s engagement in the dementia 19 
work up. Yet, time constraints was the most stated reason for non-engagement. 20 
Key words: Alzheimer’s disease; dementia; general practice; Clock Drawing Test (CDT); Mini-21 
Mental Status Examination (MMSE); primary care 22 
 23 
 24 
 25 
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1. Introduction 26 
According to the Alzheimer Report 2015 46.8 million people worldwide were living with dementia 27 
in 2015. Eventually, this number will almost double every 20 years, reaching 75 million in 2030 28 
and 131 million in 2050 (1). In 2014, Margaret Chang, the chair of WHO stated, “Dementia is not 29 
just a public health priority, it is a public policy priority” (2). The G8 dementia research summit 30 
recently described dementia as “a growing global health problem”. The average prevalence of 31 
dementia in 28 European Countries is 1.55 % (3). Primary care physicians (PCPs) may play a 32 
central role both in diagnosing dementia and in its further management, yet early dementia is often 33 
difficult to diagnose and to distinguish from normal aging in primary care (4-6). Some studies show 34 
that more than 50% of persons with dementia have never received a diagnosis of dementia from a 35 
physician (7). A 2012 review showed that 14-33% of mild dementia and 28-61% of moderate to 36 
severe dementia cases were diagnosed in primary care (8-11). In the short-term, timely diagnosis 37 
ensures access to psychosocial and pharmacological interventions . The role of primary care 38 
physicians for timely dementia detection and treatment can be cost-effective since it may improve 39 
symptoms enough to reduce healthcare costs and keep patients living in the community for longer 40 
(7, 12, 13).This contrasts to a low rate of utilization of standardized dementia tests in primary care, 41 
and little is known about how PCPs detect dementia (14). Recurring reasons to explain why 42 
accurate dementia evaluations are not done are: insufficient time, difficulty in accessing and 43 
communicating with specialists and community social service agencies, low reimbursement, and 44 
lack of interdisciplinary teams (14-16). 45 
Some PCPs seem to think that diagnosing dementia early is not particularly important and may in 46 
fact be harmful to certain patients (4). They are skeptical about the advantages of dementia 47 
medications and assess the need for a formal diagnosis of dementia within the broader context of 48 
older patients’ lives. They are more likely to pursue a formal diagnosis in situations where it 49 
benefits their patients such as accessing specific dementia services (4). Another important factor is 50 
that dementia is still a stigma in some settings (17). Although a majority of individuals with or 51 
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without cognitive impairment may prefer to be informed about a diagnosis of dementia for reasons 52 
pertaining to autonomy (18) PCPs do not always feel comfortable in breaking the bad news. Many 53 
physicians also fear to harm the relationship with their patients (19) and therefore disclosing a 54 
dementia diagnosis should align with the patient’s preferences, culture, educational level, and 55 
abilities.  56 
The Alzheimer Europe association’s report on dementia management in Europe shows 57 
heterogeneity. In some countries PCPs are allowed to establish a diagnosis of dementia and start 58 
specific drug treatment reimbursed by universal health care insurance (20). In other countries only 59 
secondary care specialists such as neurologists, geriatricians and psychiatrists are allowed to 60 
diagnose and treat dementia (3).  No studies have compared dementia management by PCPs in 61 
different European countries. Many new short cognitive tests for primary care use have been 62 
introduced lately, but few studies have explored the actual use of these tests in real life primary 63 
care. 64 
The aim of this study was to audit the involvement of PCPs in dementia management across 25 65 
European and Mediterranean countries and explore attitudes of PCPs beyond national guidelines. 66 
 67 
 68 
2. Methods 69 
This study was based on a key informant survey and was carried out by collecting questionnaires 70 
from 25 member countries of the European General Practice Research Network (EGPRN) . The 71 
steering committee of this project, called the PreDem study, developed a semi-structured 72 
questionnaire with seven multiple choice questions with space for free text comments and the eighth 73 
question requesting an optional short case story of a dementia patient from the informants own 74 
practice. Data from the Alzheimer Europe report 2012 (3) inspired many of the questions. The 75 
questionnaire’s English version is found in Appendix 1. The informants were all practicing PCPs 76 
and were asked to give the general view of the attitude of PCPs in their country. For the 25 77 
6 
 
countries, national coordinators were identified and contacted face to face by the first author during 78 
eight meetings of the European General Practice Research Network and Wonca Europe conferences 79 
in 2013-2015. National coordinators were responsible to translate the questionnaire into their own 80 
languages and to disseminate the questionnaires to at least 15 key informants for countries with a 81 
population of >10 million inhabitants, a smaller sample was accepted for smaller countries. A back 82 
translation into English was finally performed for every country by the national key informants. A 83 
convenience sampling technique was used when national key informants chose informants from 84 
different geographical regions within the same country. 85 
 86 
2.1. Statistical analyses 87 
Descriptive statistics were conducted using IBM SPSS Statistics for Windows, Version 22.0. (IBM, 88 
Armonk, NY USA, 2013). Two by two contingency tables with odds ratios and its 95% confidence 89 
interval were used to measure the association between categorical variables. A multinomial logistic 90 
regression model was used to assess the association of multiple variables (age class, gender and 91 
prescription rules) with the ordinal response data (attitude to start dementia evaluation by GPs) with 92 
a statistical significance threshold of 0.05. 93 
To check for the association between the right to prescribe and being responsible for dementia 94 
management; (the association between the right to prescribe and the attitude to establish the 95 
diagnosis of dementia on their own and the association between the right to prescribe dementia 96 
drugs and non-referral to secondary care specialists) we grouped always and often as positive 97 
responses and rarely and never as negative responses. 98 
3. Results 99 
We collected 445 questionnaires from PCP informants in 25 European and Mediterraneancountries. 100 
The distribution of informants divided by gender is presented in Table I along with population data 101 
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and dementia prevalence for each country. The age class distribution of the informants is illustrated 102 
in Figure 1. 103 
3.1.1 Question 1: “Which healthcare professionals are officially responsible for the diagnosis of 104 
dementia?” 105 
There was not unanimity between informants within the same country. In the following 15 countries 106 
two thirds or more of the informants answered that PCPs alone or in combination with secondary 107 
care specialists are officially responsible for the diagnosis of dementia: Belgium 67%, Denmark 108 
85% , Germany 100%, Greece 67%, Hungary 71%, Ireland 100%, Italy 66%, Norway 94%, Poland 109 
80%, Portugal 80%, Spain 75%, Sweden 85%, Switzerland 89%, The Netherlands 94%, United 110 
Kingdom 71%. In two countries two thirds or more of the informants answered that PCPs alone or 111 
in combination with secondary care specialists  are not officially responsible for the diagnosis of 112 
dementia: Finland 87% and Romania 69%. In 8 countries the informants’ responses were 113 
undecided: Austria, Bulgaria, Croatia, France, Israel, Malta, Slovenia, Turkey. 114 
 115 
3.2 Question 2: “Which are the most popular dementia screening tests used?” 116 
The results are illustrated in Table II and shows that the MMSE was more popular than the CDT in 117 
all countries except Hungary and was a mandatory test in 12 countries. 118 
 119 
3.3 Question 3: “Are primary care physicians allowed to start prescribing drug treatment for 120 
dementia?” 121 
In 16 countries a majority of the informants answered “YES” to the question: Austria 63%, 122 
Bulgaria 73%, Denmark 77%, Finland 67%, France 61%, Germany 100%, Greece 83%, Hungary 123 
96%, Ireland 100%, Malta 83%, Norway 100%, Poland 83%, Portugal 60%, Sweden 100%, 124 
Switzerland 100%, The Netherlands 72%. 125 
In eight countries a majority of the informants answered “NO”: Croatia 86%, France 81%, Israel 126 
87%, Italy 78%, Slovenia 80%, Spain 94%, Turkey 85%, United Kingdom 86%. In Belgium the 127 
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responses were split 50%/ 50%. 128 
 129 
3.4  Question 4 “Is continued dementia drug treatment reimbursed if prescribed by GPs /primary 130 
care physicians in your country?” 131 
In 20 countries a majority of the informants answered “YES” to the question: Austria 56%; 132 
Belgium 91%, Denmark 92%, Finland 67%, France 83%, Germany 100%, Greece 92%, Hungary 133 
89%, Ireland 100%, Israel 53%, Norway 94%, Poland 96%, Slovenia 100%, Sweden 100%, 134 
Switzerland 97%, The Netherlands 100%, Turkey 84%, United Kingdom 59%. 135 
In five countries most of the informants answered “NO” Bulgaria 73%, Italy 83%, Malta 67%, 136 
Portugal 84%, Romania 75%.  137 
 138 
3.5 Question 5: “Do primary care physicians try to establish a diagnosis of dementia on their 139 
own?”  140 
The outcomes for this question are illustrated in Table III and shows that in 13 countries two thirds 141 
or more of the informants responded that PCPs always or often tries to establish a diagnosis of 142 
dementia on their own: Austria 69%; France 92%, Germany 87%, Greece 75%, Ireland 75%, 143 
Israel 67%, Norway 95%, Portugal 70%, Slovenia 80%, Spain 82%, Sweden 100%, Switzerland 144 
97%, The Netherlands 72%. In six countries a majority of the informants responded that PCPs 145 
rarely or never tries to establish a diagnosis of dementia on their own: Finland 86%, Hungary 146 
61%, Malta 50%, Poland 79%, Romania 62% and Turkey 89%. In six countries the informants’ 147 
responses were undecided: Belgium, Bulgaria, Croatia, Denmark, Italy, United Kingdom. 148 
 149 
3.6 Question 6: “Do primary care physicians refer a suspected case of dementia to a secondary 150 
care specialist?”  151 
The outcomes for this question are illustrated in Table IV and show that in 21 countries two thirds 152 
or more of the informants responded that PCPs always or often referred a suspected case of 153 
dementia to a secondary care specialist. In four countries: Norway 39%, Sweden 84%, Switzerland 154 
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50% and the Netherlands 44% of informants responded that PCPs rarely or never referred a 155 
suspected case of dementia to a secondary care specialist. 156 
 157 
3.7 Question 7: “What would primary care physicians need to be able to detect dementia better?”  158 
Results are presented in Table V and show that in 17 countries more time was mentioned as a need 159 
by a majority of the informants: Austria; France, Germany, Greece, Ireland, Israel, Norway, 160 
Slovenia, Spain, Sweden, Switzerland, The Netherlands, UK, Turkey. In eight countries more time 161 
was mentioned by a minority of the informants: Belgium, Croatia, Finland, France, Italy, Malta, 162 
Portugal and Romania. In 12 countries short tools was mentioned as a need by a majority of the 163 
informants: Austria, Belgium, Germany, Greece, Hungary, Israel, Italy, Poland, Romania, Spain, 164 
Switzerland and Turkey. 165 
In four countries incentives was mentioned as a need by a majority of the informants: Austria, 166 
Greece, Ireland, and UK. 167 
 168 
 169 
3.8.1 Association between the right to prescribe and being responsible for dementia management. 170 
 Association between right to start drug treatment and being responsible for dementia 171 
management: Odds Ratio, 3.45; 95% CI, 2.28- 5.23. 172 
 Association between right to continue drug treatment and being responsible for dementia 173 
management: Odds Ratio, 2.29; 95% CI, 1.49-3.52 174 
3.8.2 Association between the right to prescribe and attitude to establish the diagnosis of dementia 175 
on their own:  176 
 Association between right to start drug treatment and attitude to establish the diagnosis of 177 
dementia on their own Odds Ratio, 1.64; 95% CI, 1.11-2.41. 178 
 Association between right to continue drug treatment and attitude to establish the diagnosis 179 
of dementia on their own Odds Ratio, 1.77; 95% CI, 1.16-2.68. 180 
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3.8.3 Association between the right to prescribe dementia drugs and non-referral to secondary care 181 
specialists. 182 
 Association between the right to start drug treatment and non-referral to secondary care 183 
specialists Odds Ratio, 3.83; 95% CI 2.18- 6.73. 184 
 Association between the right to continue drug treatment and non-referral to secondary care 185 
specialists Odds Ratio, 2.08; 95% CI 1.19; 3.64. 186 
3.8.4  Multivariate analysis 187 
No significant association between gender of the informants and the outcome was found (Chi 188 
Square (3, n=437) 0.20, p=0.98) while age was statistically associated with the outcome (Chi 189 
Square  12, n=437) 47.52, p<0.001). 190 
Post hoc analysis showed that informants  30 years old or younger were less likely to respond that 191 
PCPs tend to start dementia evaluation (Chi Square (12, n=437) 47.70, p<0.001). 192 
 193 
 194 
 195 
4. Discussion  196 
This physician informant survey of dementia management in primary care across 25 European and 197 
Mediterranean countries show that most PCPs are engaged in dementia work-up.  In many countries 198 
they also prescribe dementia drugs but the degree of their engagement varies greatly between 199 
countries. A high consistency of responses was found in countries with permissive rules for PCPs 200 
diagnosing and prescribing dementia drugs whilst there were many missing responses in countries 201 
with less permissive rules and where the prevalence of dementia is lower.    202 
This first question in the survey of who was officially responsible for the diagnosis of dementia was 203 
inspired by the Alzheimer Report (3). Our hypothesis was that there would be an association 204 
between responsibility of diagnosing and reimbursement of dementia drug costs from the health 205 
care insurance if prescribed by PCPs without a previous prescription of the secondary care 206 
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specialist. The positive association that we did find between the right to prescribe dementia drugs 207 
and being responsible for the dementia work-up was stronger for the right to write the first 208 
prescription by a primary care physician than only being allowed to continue a prescription first 209 
issued by a secondary care specialist.   210 
The Mini-Mental State Examination (MMSE) was the most popular cognitive test either used alone 211 
or in combination with other tests. The Clock Drawing Test (CDT) was the second most popular. 212 
Other tests (21-23) were not so popular and were used sporadically. In many countries MMSE was 213 
mandatory before prescription of dementia drugs. In other countries it was just recommended. 214 
Turkey had the highest number of missing data which is probably related to the low dementia 215 
prevalence in that country. In France no test was mandatory and the “5 words of Dobois”  and the 216 
instrumental activities of daily living tool (IADL)  were popular tests.  PCPs from Finland and 217 
United Kingdom had the highest percentage of suggested alternative tests (7).  In Finland The 218 
Consortium to Establish a Registry for Alzheimer’s Disease (CERAD) was frequently used while 219 
many UK PCPs reported the use of the Six Item Cognitive Impairment Test (6-CIT)  and  the 220 
General Practitioner Assessment of Cognition (GPCOG). 221 
According to the official rules and guidelines at the time of data collection (3) only in Germany, 222 
Ireland, Norway, Sweden and Switzerland did PCPs have the right to prescribe memantine and 223 
cholinesterase inhibitors. In Austria, Bulgaria, Denmark, Finland, Greece, Hungary, Malta, The 224 
Netherlands, Poland and Portugal it appears that informants were in reality entitled to prescribe 225 
even if officially they were not. A possible cause for this discrepancy is that with the advent of 226 
cheap generic drugs, reimbursement is not a big problem in most countries. In France PCPs were 227 
not entitled to prescribe dementia drugs for the first time but apparently many did prescribe anyway 228 
according to the open comments in our survey. In Hungary dementia was treated in primary care 229 
with piracetam and vinpocetin according to open comments. In Malta and Bulgaria where 230 
cholinesterase inhibitors or memantine were not reimbursed even if prescribed by secondary care 231 
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specialists PCPs were prescribing these drugs to a higher degree. In Bulgaria nicergoline, and 232 
piracetam were reimbursed even if the efficacy of the latter is controversial. 233 
There was incongruence between the survey responses and the restrictive prescribing rules in Spain, 234 
Hungary, Denmark, Austria and Belgium.  In France the answer was officially “YES” but there was 235 
a misunderstanding of a compulsory requirement of a yearly assessment by a secondary care 236 
specialist by some of the PCPs according to open comments.  Possible explanations of the 237 
discrepancies between the official rules/guidelines and the PCP’s responses to questions 1, 3 and 4, 238 
are: i) different perceptions of rules/guidelines, ii) the willingness of some physicians to bend rules 239 
iii)more than one set of rules in each country (in different regions or for different health care 240 
insurers). These explanations find support in the rich data from the free text comments to the 241 
survey.  242 
Difficulties in understanding the questionnaire might be another possible explanation to the 243 
discrepancies. Consistency between the official rules/guidelines and PCP’s responses appear to be 244 
better in countries with more permissive regulations (Sweden, Germany, Switzerland, Norway and 245 
Ireland). 246 
 247 
According to this 2015 audit, European and Mediterranean PCPs seemed to be willing to start 248 
dementia work-up, but time constraints was the major barrier (19, 24-28). In France many 249 
informants stated that money incentives could help. In Sweden and Norway PCPs normally have 15 250 
to 20 minutes’ consultations. They can, however, plan a longer time and organize multiple 251 
consultations, which is recommended when diagnosing dementia.  252 
In the last decades drug expenditure has been one of the major concerns in many European health 253 
care systems.  According to the World Alzheimer report 2015 (1) only 20% of the cost of dementia 254 
care are for medical purposes and the medical costs decrease with an earlier, accurate diagnosis (29, 255 
30).   256 
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This 2015 audit study from most European countries, Israel and Turkey, may have implications for 257 
health care planning and future research in how to manage cognitive impairments facing our ageing 258 
global population.   259 
 260 
Limitations of the study:  Since we used a convenience sample of informants the 261 
representativeness of PCPs for each country may be questionable although we tried to achieve 262 
geographical variation. Our questionnaire, inspired by the Alzheimer Europe report is simple but 263 
piloted, developed in a multi-step process with experts in the field, but not validated against other 264 
measures apart from a face validation procedure.  265 
We cannot rule out the possibility of confounding or alternative explanations to our results since the 266 
survey responses show attitudes and not actual performance.  267 
5. Conclusion 268 
According to this 2015 audit to 445 European and Mediterranean  PCPs most seem willing to start 269 
dementia work-up with time constraints as the major barrier. The MMSE was the most popular 270 
cognitive test followed by the CDT. It seems that official rules affect attitudes to dementia work-up 271 
and PCPs that are not entitled to prescribe dementia drugs are more inclined to refer patients with 272 
suspected dementia to secondary care.  273 
 274 
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Table I 373 
Population characteristics, dementia prevalence and primary care physicians (PCPs) as 374 
key informants in the PreDem - a dementia management study from 25 countries in the 375 
EGPRN (European General Practice Research Network)* 376 
 377 
Country Population 
million 
people 
Population 
65 years 
old or over 
% 
Dementia 
prevalence 
% 
Primary care physician 
key informants, n (%) 
Men Women Total 
Austria 8.6 18.3 1.73 10 (53) 9 (47) 19 
Belgium 11.3 17.8 1.77 6 (50) 6 (50) 12 
Bulgaria 7.2 19.6 1.49 3 (20) 12 (80) 15 
Croatia 4.2 18.4 1.53 4 (19) 17 (81) 21 
Denmark 5.8 18.2 1.53 10 (77) 3 (23) 13 
Finland 5.5 19.4 1.71 6 (40) 9 (60) 15 
France 66.4 18.0 1.85 15 65) 8 (35) 23 
Germany 81.2 20.8 1.92 5 (31) 11 (69) 16 
Greece 10.8 20.5 1.77 3 (25)  9 (75) 12 
Hungary 9.8 17.5 1.50 16 (57) 12 (43) 28 
Ireland 4.6 12.6 1.08 7 (87) 1 (13) 8 
Israel 8.5 10.3 1.10 8 (53) 7 (47) 15 
Italy 60.6 21.4 2.09 19 (83) 4 (17) 23 
Malta 0.4 17.9 1.26 5 (83) 1 (17) 6 
Norway 5.2 15.9 1.56 11 (61) 7 (39) 18 
Poland 38.0 14.9 1.31 9 (38) 15 (62) 24 
Portugal 10.4 19.9 1.71 5 (25) 15 (75) 20 
Romania 19.9 16.5 1.26 2 (13) 14 (87) 16 
Slovenia 2.1 17.5 1.57  5(100) 5 
Spain 46.4 18.1 1.75 9 (56) 7 (44) 16 
Sweden 9.7 19.4 1.82 8 (61) 5 (39) 13 
Switzerland 8.2 17.6 1.73 31 (82) 7 (18) 38 
The Netherlands 16.9 17.3 1.47 9 (50) 9 (50) 18 
Turkey 77.7 7.7 0.44 12 (35) 22 (65) 34 
United Kingdom 64.8 17.5 1.65 7 (41) 10 (59) 17 
TOTAL 584.1  1.55 220 (49) 225 (51) 445  
 378 
*Values are given in percent (%) and absolute numbers (n). 379 
†Data for dementia prevalence by the Alzheimer Europe Association, 2013. 380 
 381 
  382 
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Table II  383 
“Which are the most popular dementia screening tests used? “ 384 
 385 
Country MMSE  (MMSE 
mandatory) 
CDT  Other 
tests 
 % (n)  % (n) % (n) 
Austria 95 18 YES 53 10   
Belgium 99 12 YES 8 1   
Bulgaria 67 10 NO 34 5 7 1 
Croatia 100 21 NO 5 1 5 1 
Denmark 100 13 NO 23 3 15 2 
Finland 76 13 NO 46 7 59 9 
France 100 23 YES 74 17 39 9 
Germany 88 14 NO 13 2 6 1 
Greece 100 12 NO 16 2 8 1 
Hungary 60 17 YES 82 23   
Ireland 100 8 NO 13 1 13 1 
Israel 100 15 NO 27 4   
Italy 91 21 YES 25 6 8 2 
Malta 100 6 NO     
Norway 95 17 YES 84 15 6 1 
Poland 80 19 YES 54 13 12 3 
Portugal 90 18 NO 20 4 5 1 
Romania 82 13 YES 63 10   
Slovenia 100 5 YES 60 3   
Spain 94 15 YES 26 4 13 2 
Sweden 100 13 NO† 54 7 8 1 
Switzerland 68 26 YES 32 12   
The 
Netherlands 
94   17 YES 61 11 11 2 
Turkey 56 19 NO 18 6   
United 
Kingdom 
47 8 NO 12 2 41 7 
 386 
Abbeviations: MMSE, Mini Mental State Examination; CDT, Clock Drawing Test. 387 
*Values are given in percent (%) and absolute numbers (n). 388 
† in Sweden the MMSE is not mandatory but recommended  389 
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Table III     390 
“Do primary care physicians try to establish a diagnosis of dementia on their own?”* 391 
 392 
Country Always  Often 
 
Rarely Never Missing 
 % (n) % (n) % (n) % (n) % (n) 
Austria 11 2 58 11 26 5   5 1 
Belgium   58 7 42 5     
Bulgaria 20 3 33 5 40 6 7 1   
Croatia 5 1 48 10 43 9 5 1   
Denmark 8 1 54 7 31 4 8 1   
Finland 7 1 7 1 73 11 13 2   
France 35 8 57 13 9 2     
Germany 6 1 81 13 6 1   6 1 
Greece 25 3 50 6 25 3     
Hungary   39 11 54 15 7 2   
Ireland   75 6 25 2     
Israel   67 10 33 5     
Italy 9 2 44 10 35 8 9 2 4 1 
Malta   33 2 50 3   17 1 
Norway 6 1 89 16 6 1     
Poland   21 5 71 17 8 2   
Portugal 5 1 65 13 25 5   5 1 
Romania   38 6 56 9 6 1   
Slovenia   80 4     20 1 
Spain 19 3 63 10 19 3     
Sweden 31 4 69 9       
Switzerland 5 2 92 35 3 1     
The 
Netherlands 
  72 13 17 3 6 1 6 1 
Turkey   9 3 77 26 12 4 3 1 
United 
Kingdom 
  59 10 41 7     
 393 
*Values are given in percent (%) and absolute numbers (n). 394 
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Table IV     395 
“Do primary care physicians refer a suspected case of dementia to a secondary care 396 
specialist?”* 397 
 398 
Country Always Often Rarely Never Missing 
 % (n) % (n) % (n) % (n) % (n) 
Austria 32 6 58 11 5 1 
  
5 1 
Belgium 17 2 67 8 17 2 
    
Bulgaria 67 10 27 4 
    
7 1 
Croatia 24 5 62 13 14 3 
    
Denmark 31 4 62 8 8 1 
    
Finland 40 6 60 9 
      
France 26 6 61 14 13 3 
    
Germany 19 3 50 8 25 4 
  
6 1 
Greece 17 2 75 9 8 1 
    
Hungary 18 5 75 21 7 2 
    
Ireland 38 3 63 5 
      
Israel 27 4 73 11 
      
Italy 48 11 44 10 
  
4 1 4 1 
Malta 17 1 83 5 
      
Norway 
  
50 9 39 7 
  
11 2 
Poland 21 5 71 17 8 2 
    
Portugal 25 5 65 13 5 1 
  
5 1 
Romania 81 13 19 3 
      
Slovenia 40 2 60 3 
      
Spain 56 9 44 7 
      
Sweden 8 1 8 1 84 11 
    
Switzerland 3 1 47 18 50 19 
    
The 
Netherlands 
6 1 50 9 44 8 
    
Turkey 38 13 47 16 15 5 
    
United 
Kingdom 
18 3 71 12 12 2 
    
 399 
*Values are given in percent (%) and absolute numbers (n). 400 
 401 
 402 
 403 
 404 
 405 
 406 
 407 
 408 
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Table V   409 
“What would primary care physicians need to be able to detect dementia better?” More 410 
than one option is possible*  411 
Country Short tools Incentives More time for consultation   
 
 
% (n) % (n) % (n) 
Austria 63 12 63 12 58 11 
Belgium 92 11 8 1 42 5 
Bulgaria 47 7 27 4 80 12 
Croatia 14 3 5 1 38 8 
Denmark 46 6 8 1 62 8 
Finland 20 3 
  
47 7 
France 43 6 9 2 35 8 
Germany 63 10 13 2 81 13 
Greece 83 10 50 6 92 11 
Hungary 61 17 43 12 82 23 
Ireland 38 3 50 4 100 8 
Israel 73 11 33 5 87 13 
Italy 61 14 4 1 30 7 
Malta 17 1 
  
17 1 
Norway 39 7 17 3 61 11 
Poland 63 15 29 7 83 20 
Portugal 10 2 
  
45 9 
Romania 94 15 18 3 38 6 
Slovenia 
  
20 1 100 5 
Spain 63 10 
  
81 13 
Sweden 46 6 15 2 77 10 
Switzerland 58 22 11 4 66 25 
The Netherlands 39 7 22 4 56 10 
Turkey 79 27 27 9 65 22 
United Kingdom 18 3 53 9 71 12 
 412 
*Values are given in percent (%) and absolute numbers (n). 413 
 414 
 415 
 416 
 417 
 418 
 419 
 420 
  421 
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 422 
Figure 1 : Age groups of the informants (years) 
I: < 30;  II: 31-40; III: 41-50; IV: 51-60; V: > 61; 
 
 
